Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE - an enhanced deconvolution method
暂无分享,去创建一个
Mónica Balzarini | Gabriel A. Rabinovich | Elmer A. Fernández | Yamil D. Mahmoud | Florencia Veigas | Darío Rocha | Matías Miranda | Joaquín Merlo | Hugo D. Lujan | María Romina Girotti | E. Fernández | G. Rabinovich | M. Balzarini | H. Luján | M. R. Girotti | Florencia Veigas | Darío Rocha | Joaquín P. Merlo | Matías Miranda
[1] Eytan Ruppin,et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma , 2018, Nature Medicine.
[2] Ash A. Alizadeh,et al. Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.
[3] M. Balzarini,et al. Bedside Linear Regression Equations to Estimate Equilibrated Blood Urea , 2011 .
[4] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[5] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[6] P. Laurent-Puig,et al. TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma , 2018, Clinical Cancer Research.
[7] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[8] X. Shirley Liu,et al. Revisit linear regression-based deconvolution methods for tumor gene expression data , 2017, Genome Biology.
[9] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[10] A. Beckett,et al. AKUFO AND IBARAPA. , 1965, Lancet.
[11] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Martin L. Miller,et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma , 2019, Cell.
[13] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[14] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[15] D. Schadendorf,et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.
[16] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[17] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.
[18] E. D. de Vries,et al. Tumor-associated macrophages in breast cancer: Innocent bystander or important player? , 2018, Cancer treatment reviews.
[19] M. Hou,et al. Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer , 2018, BMC Cancer.
[20] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[21] Kaanan P. Shah,et al. Integrated genomic profiling expands clinical options for patients with cancer , 2019, Nature Biotechnology.
[22] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[23] L. Lynch,et al. γδ T cells in cancer: a small population of lymphocytes with big implications , 2019, Clinical & translational immunology.
[24] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[25] Ajay Goel,et al. Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.
[26] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[27] N. Samadi,et al. Tumor microenvironment-mediated chemoresistance in breast cancer. , 2016, Breast.
[28] Z. Stadler,et al. Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.
[29] S. Leung,et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration , 2014, Breast Cancer Research.
[30] N. Hacohen,et al. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.
[31] Yu Wang,et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data , 2017, Genome Medicine.
[32] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[33] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[34] J. Pollard,et al. Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.
[35] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[36] Nijiati Aierken,et al. Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis , 2017, Journal of Cancer.
[37] Z. Trajanoski,et al. Next-generation computational tools for interrogating cancer immunity , 2019, Nature Reviews Genetics.
[38] P. Hegde,et al. Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.
[39] Michael Peyton,et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.
[40] Z. Trajanoski,et al. Quantifying tumor-infiltrating immune cells from transcriptomics data , 2018, Cancer Immunology, Immunotherapy.
[41] A. Regev,et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma , 2019, Nature Medicine.
[42] Z. Modrušan,et al. Deconvolution of Blood Microarray Data Identifies Cellular Activation Patterns in Systemic Lupus Erythematosus , 2009, PloS one.
[43] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[44] Renaud Gaujoux,et al. CellMix: a comprehensive toolbox for gene expression deconvolution , 2013, Bioinform..
[45] Laurence Zitvogel,et al. The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.
[46] M. Ceccarelli,et al. RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types , 2019, Cell reports.
[47] Yamil D. Mahmoud,et al. Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation , 2019, Cancer cell.
[48] A. Cesano. nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA) , 2015, Journal of Immunotherapy for Cancer.
[49] Jay Shendure,et al. Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.
[50] D. Schadendorf,et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.
[51] Francisco Avila Cobos,et al. Computational deconvolution of transcriptomics data from mixed cell populations , 2018, Bioinform..
[52] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[53] Barbara B. Shih,et al. Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors , 2018, Cancer Immunology Research.
[54] P. Altevogt,et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors , 2004 .
[55] A. Butte,et al. xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, Genome Biology.
[56] T. Chan,et al. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.
[57] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[58] Brian Ruffell,et al. Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.